Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. The Apellis acquisition is framed as a successful integration milestone, with management citing continuity of revenue during organizational turbulence as the primary metric of success. Operational overhauls in the research organization ended a three-year IND drought, with three filings already in 2026 aimed at securing growth into the mid-2030s. The LEQEMBI IQLIK (subcutaneous) approval is viewed as a critical tool to reduce patient drop-off by removing the logistical barriers associated with biweekly infusions.